Journal
BIOMATERIALS ADVANCES
Volume 134, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.msec.2021.112539
Keywords
Bone; Bone morphogenetic protein-2; Calcium sulfate; Gelatin; Hydroxyapatite; Osteoporosis
Categories
Funding
- Spanish Ministry of Economy, Industry and Competitiveness [PID2019-106094RB-I00/AEI/10.13039/501100011033]
- Basque Country Government [PRE_2020_2_0042, IT907-16]
- European Union [951747]
Ask authors/readers for more resources
In this study, a new osteoconductive scaffold was developed, which reduced the required doses of BMP-2 for bone regeneration. The scaffold showed promising results in promoting cell adhesion, proliferation, and osteogenic differentiation of human bone-marrow derived mesenchymal stem cells (hBM-MSCs). The sustained release of BMP-2 from the scaffold allowed for the treatment of critical-sized osteoporotic bone defects with relatively low growth factor doses.
There are currently several commercialized products approved by the Food and Drug Administration and the European Medicines Agency based on the use of recombinant human BMP-2 for the treatment of non-unions long fractures and spinal fusion. However, the adverse effects recorded with the use of BMPs suggest the need for drug delivery carriers that allow reducing the required doses and improve their cost-effectiveness. herein, we have developed a new osteoconductive scaffold that reduces the required doses of BMP-2 for promoting bone regeneration in an osteoporotic defect model. The composite is, in brief, a gelatin-based 3D scaffold reinforced with either calcium sulfate or hydroxyapatite as an inorganic osteoconductive biomaterial. To this end, the organic/inorganic composite systems showed high hydration capacity and good in vitro degradability. The incorporation of 7.5% (m/v) ceramic compounds resulted in scaffolds with stiffer Young modulus (179 and 75 kPa for CaSO(4-)7 and HA(-)7, respectively) than bare gelatin hydrogels (48 kPa). Studies with human bone-marrow derived mesenchymal stem cells (hBM-MSCs) revealed that the 3D scaffolds promote cell adhesion and proliferation along with osteogenic differentiation capabilities. Specifically, downregulation of sternness (Nanog, Oct4) genes and upregulation of osteogenic markers (ALP, Col1a1, Fmod) by two fold were observed over 10 days under basal culture conditions. Promisingly, the sustained in vitro release of BMP-2 observed from the porous reinforced scaffolds allowed us to address the critical-sized osteoporotic mice calvarial defects with a relatively low growth factor doses (600 ng BMP-2/scaffold) compared to conventional doses at 2-15 micrograms. Overall, this study demonstrates the promising potential of osteoconductive gelatin/calcium bioceramics composites as osteogenic growth factors delivery carriers for bone-regeneration via ultra-low growth factor doses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available